A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and PK of ATTO1310 in Adult Volunteers, Patients With Atopic Dermatitis, and Patients With Chronic Pruritus
Latest Information Update: 13 May 2025
At a glance
Most Recent Events
- 18 Mar 2025 Planned number of patients changed from 80 to 104.
- 29 Jan 2025 New trial record
- 23 Jan 2025 According to the Attovia Therapeutics the Media Release, first subject has been dosed in a first-in-human Phase 1 study.